Analysis Of The Current Status Of Drug Use In Patients With Heart Failure With Reduced Ejection Fraction—A Single-Center Clinical Investigation

Aims:Heart failure is a clinical syndrome caused by a decrease in the pumping and/or congestion capacity of the heart.With the deepening of research on heart failure,new anti-heart failure drugs have received evidence-based support.In 2021,countries around the world successively released new guidelines for the treatment of heart failure,opening a new chapter in the treatment of heart failure.The aim of this study is to investigate the current clinical application status of new anti-heart failure drugs in heart failure patients with reduced ejection fraction as outlined in the guidelines.Methods:The diagnosis and treatment data were extracted and analyzed from the electronic medical record system of the First Affiliated Hospital of Nanchang University from September 2020 to August 2022 for hospitalized patients who diagnosed with heart failure by clinical doctors and with left ventricular ejection fraction ≤40%indicated by cardiac ultrasound.According to the ESC Heart Failure Diagnosis and Treatment Guidelines released in August 2021,the patients from September 2020 to August 2021 was divided into Group A and from September 2021 to August 2022 into Group B.The usage of angiotensin-converting enzyme inhibitor(ACEI),angiotensin receptorneprilysin inhibitor(ARNI),beta-blockers,mineralocorticoid receptor antagonist(MRA)and sodium-glucose co-transporter 2(SGLT2)inhibitors between the two groups were counted and analyzed.Results:This survey included 412 patients,including 190 in Group A and 222 in Group B.The investigation found that ARNI had completely replaced ACEI,and the usage rate of ARNI drugs is 96.3%in Group A and 91.0%in Group B;beta-blockers drugs is 77.0%in Group A and 83.8%in Group B;mineralocorticoid receptor antagonist drugs is 91.1%in Group A and 91.4%in Group B;sodium glucose co-transporter 2 inhibitors is 18.9%in Group A and 36.5%in Group B;The usage rates of the "Golden Triangle" treatment plan were 63.2%in Group A and 73.4%in Group B.The "New Quadruple" treatment plan was only used by 68 patients in Group B,less than one-third(30.6%).Conclusion:The survey results show that ARNI drugs in our hospital had completely replaced ACEI drugs,the use rate of beta-blockers drugs had increased compared with the previous one,and the use rate of MRA drugs had not changed much.Although the use rate of SGLT2 inhibitors had increased since the 2021ESC heart failure guidelines published and it is not limited to use only in patients with diabetes,there is still a large gap compared with the use rate of the former three.And the use rate of the "new quadruplex" treatment scheme is also to be unsatisfied.